QL1706 for the Neoadjuvant Treatment of HR+/HER2- Breast Cancer

NCT06967103 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

238

Enrollment

OTHER_GOV

Sponsor class

Conditions

Breast Cancer
HR+/HER2- Breast Cancer

Interventions

DRUG: QL1706
DRUG: Nab-PE

Sponsor

Henan Cancer Hospital